

# Medicines and Medical Devices Bill

---

AMENDMENTS  
TO BE MOVED  
IN GRAND COMMITTEE

---

**Clause 2**

LORD PATEL

Page 2, line 35, at end insert—

- “( ) Regulations under section 1(1) must make provision to enable the Medicines and Healthcare products Regulatory Agency to work with other regulators to minimise delay for the United Kingdom to get early access to new medicines.”

**Clause 4**

LORD PATEL

Page 3, line 25, at end insert—

- “( ) to develop a clinical trials portal that aligns with the European Medicines Agency for medicines for rare diseases.”

**After Clause 38**

BARONESS CUMBERLEGE

Insert the following new Clause—

**“Independent medicines and medical devices safety review: task force for implementation**

- (1) Within three months of this Act being passed, the Secretary of State must appoint an independent task force.
- (2) The task force must—
  - (a) have an independent Chair;
  - (b) be accountable to an oversight governance board; and
  - (c) include representatives of the Independent Medicines and Medical Devices Safety Review, published on 8 July 2020.
- (3) The task force’s functions are—
  - (a) to deliver a timeline for the implementation in full of the recommendations of the Review in subsection (2)(c); and
  - (b) to implement the recommendations of the Review in subsection (2)(c).

**After Clause 38 - continued**

- (4) Once the task force has fulfilled the functions in subsection (3), it will cease to exist.”

# Medicines and Medical Devices Bill

---

AMENDMENTS  
TO BE MOVED  
IN GRAND COMMITTEE

---

*7 September 2020*

---